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alone. These results corresponded to an incremental cost-
effectiveness ratio (ICER) equivalent to SR20,423 (US$5,439)
per life-year gained and SR21,857 (US$5,821) per QALY gained.
Sensitivity analyses showed these results to be robust under a
range of plausible assumptions. CONCLUSIONS: Adjuvant
treatment with trastuzumab in HER2+ early breast cancer was
estimated to be a cost-effective treatment option over patients’
lifetimes in Saudi Arabia, attributed to improvements in life
expectancy and QALYs that translate into a high net beneﬁt to
the society.
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OBJECTIVES: To evaluate the cost-effectiveness of lapatinib plus
capecitabine (L + C) vs. currently used regimens in Finland for
women with HER2+ metastatic breast cancer which has pro-
gressed following trastuzumab treatment. METHODS: A
survival analysis model with a lifetime timeframe was used to
calculate expected costs, Life Years (LYs), and Quality Adjusted
Life Years (QALYs) for L + C vs. usual care in women with
HER2+ MBC who have progressed following trastuzumab treat-
ment. Usual care was represented as a weighted average of
currently-used treatments in Finland, including continued
trastuzumab-based therapy (50%) and single-agent chemo-
therapy (50%). The effectiveness of L + C and single-agent che-
motherapy was based on data from a phase III randomized open
label multi-centre trial comparing L + C with capecitabine alone
in women with HER2+ MBC who had received prior treatment
with an anthracycline, a taxane, and trastuzumab. Effectiveness
of trastuzumab-based therapy was based on a pooled analysis of
data from published studies. The analysis was performed from a
societal perspective. Costs were obtained from ofﬁcial price-lists.
Utilities were obtained from international publications. Costs
and outcomes were discounted at 5%, consistent with Finnish
guidelines. RESULTS: Compared with usual care, treatment with
L + C yields an additional 0.216 LYs and 0.157 QALYs at an
incremental cost of €8310. Cost-effectiveness of L + C vs. usual
care is €38,481 per LY gained and €52,911 per QALY gained.
The cost-effectiveness of L + C vs. usual care is sensitive to the
proportion of usual care patients who receive continued trastu-
zumab vs. single-agent chemotherapy. Assuming there are 130
candidates for L + C in Finland each year, the budget impact of
L + C is approximately €1M€ per year. CONCLUSIONS: For
patients with HER2+ MBC who have progressed on trastu-
zumab, treatment with L + C meets an unmet clinical need and is
cost-effective in this setting. IV administered treatment can cause
over 12,000€ additional costs per year compared with oral
formulations.
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OBJECTIVES: A randomized phase III trial of Capecitabine/
Cisplatin (XP) versus continuous infusion of 5-FU/Cisplatin (FP)
as ﬁrst-line therapy in patients with advanced gastric cancer
(AGC) met its primary endpoint of non-inferior progression-free
survival (PFS). There was a trend toward superior efﬁcacy with
XP in terms of both PFS and response rates. An economic assess-
ment was conducted in Spain to compare the costs of both
therapies considered unit costs and medical resource consump-
tion for year 2007. METHODS: Direct medical costs were esti-
mated from the Spanish National Healthcare System perspective.
The therapies costs were estimated based on the clinical trial
results on actual dose and the number of administrations, and
unit costs in different hospitals in Spain. The adverse event (AE)
proﬁles were used to estimate the costs of treating AEs. An expert
panel estimated treatment patterns and costs of treating major
AEs. Indirect costs for time and travel for drug administration
were also estimated. RESULTS: Annual pharmacologic cost in
the XP arm were estimated to be €1333 greater than in the XP
arm, but drug administration costs and AE costs were lower in
the XP arm (€2575 and €27, respectively). Overall, direct and
indirect medical costs were estimated at €2688 in the XP arm and
at €4014 in the FP arm. According to budget impact results, 1.58
patients are likely to be treated with XP for each patient treated
with FP. CONCLUSIONS: In Spain, oral capecitabine reduce the
number and time spent in infusion visits, and would produce
signiﬁcant direct medical cost savings in the treatment of patients
with AGC. Given the trend to superior efﬁcacy, the estimate
direct and indirect cost savings, and the convenience of oral
treatment, XP treatment would be considered less costly than FP
treatment for AGC from both a health care system and a societal
perspective.
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OBJECTIVES: Bone is the most common site for metastasis in
cancer and bone metastases (BM) result in considerable morbid-
ity and complex demands on health care resources. Bisphospho-
nates have been shown to treat and reduce skeletal-related events
(SREs), which reduce quality-of-life and increase the risk of
death. The aim of this study was to evaluate the cost-effectiveness
of clodronate and zoledronate in the prevention of SREs in
patients with BM. METHODS: We developed a Markov model
to represent a cohort of patients diagnosed with BM in order to
determine the cost-effectiveness of the studied therapeutic alter-
natives. The model has four health states: without SRE, with SRE
(i.e., pathologic fracture, radiotherapy or surgery, and hypercal-
cemia), osteonecrosis and death. Transition probabilities came
from SREs incidence rate meta-analysis previously performed by
our group. Economical data were obtained from national data-
bases. Univariate and multivariate sensibility analyses were used
to determine the robustness of the pharmacoeconomic model. We
used the public health perspective. Costs were presented in 2007
Brazilian Reais (1R$ = 1.60US$) RESULTS: BM treatment total
cost in Brazil (on average, per patient) in ﬁve years (base case)
was R$46,313 with clodronate and R$50,319 with zoledronate.
Drug cost was the most inﬂuential item in the overall cost of BM
treatment (>90%). In a ﬁve-year time-horizon, clodronate and
zoledronate generated (on average, per patient) 2.00 and 1.90
QALYs, respectively. In this same time-horizon, clodronate and
zoledronate also generated (on average, per patient) 1.81 and
1.76 SRE free-years, respectively. When we analyzed clodronate
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costs in relation to zolendronate per QALYs and SRE free-years
produced, zolendronate was dominated by clodronate. Multi-
variate sensibility analysis did not show changes in the initial
results of this pharmacoeconomic model CONCLUSIONS: From
the Brazilian Ministry of Health perspective, clodronate was
dominant in comparison to zoledronate in preventing SREs in
patients with BM.
PCN24
PEGYLATED LIPOSOMAL DOXORUBICIN IN COMBINATION
WITH BORTEZOMIB FORTHETREATMENT OF RELAPSED
MULTIPLE MYELOMA—A COST-EFFECTIVENESS STUDY
FOR SCOTLAND
Gibbons CJ1,Yong K2, Roberts G3
1Schering-Plough,Welwyn Garden City, UK, 2Royal Free and
University College Medical School, London, UK, 3Oxford Outcomes
Ltd, Oxford, UK
OBJECTIVES: Treatment options for patients with relapsed mul-
tiple myeloma (MM) have recently seen the addition of a number
of new therapies. Some of these may be used in combination, but
there is no clear standard of care and the relative cost-
effectiveness of the new therapies or combinations thereof
remains largely untested. Pegylated liposomal doxorubicin in
combination with botrezomib represents a new alternative whose
clinical performance appears to give better patient outcomes
(both overall survival (OS) and progression-free survival (PFS)
than bortezomib alone. To complete a technology appraisal
within the Scottish health care setting, a cost-effectiveness model
was developed comparing the combination therapy against bort-
ezomib monotherapy as well as against high-dose dexametha-
sone monotherapy. METHODS: The model used clinical
outcomes data from the licensing trials of the combination
therapy (DOXIL MMY-301 study) as well as the licensing trial
for bortezomib monotherapy (APEX study). Patient utilities
prior to and after progression were sourced from a published
cost-effectiveness study. A ten-year timeframe was assumed and
available clinical data for PFS and OS were extended using
Weibull regression methods. RESULTS: The results from our
base case analysis suggest that the combination therapy is cost-
effective compared to bortezomib monotherapy (ICER £17,303/
QALY) as well as versus high-dose dexamethasone therapy
(ICER £27,880/QALY). Incorporation of further clinical OS and
PFS statistics from a recent data update resulted in a slight
increase in ICERs, however these remained cost-effective. CON-
CLUSIONS: The model suggests that the combination therapy
would be a cost-effective addition to the Scottish treatment
paradigm.
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OBJECTIVES: Trastuzumab is a humanized monoclonal anti-
body against the extracellular domain of HER-2 and it has
activity in early and advanced breast cancer with HER-2 over-
expression. The cost-effectiveness of trastuzumab in 1 year
therapy was assessed for patients with breast cancer who had
completed loco-regional surgery and at least four cycles of neo-
adjuvant or adjuvant chemotherapy in comparison with obser-
vation from the public health care system perspective.
METHODS: This cost-effectiveness analysis was based on the
HERA trial. A modiﬁed Delphi panel with local specialists was
conducted to identify local resources usage for treating breast
cancer. Costing was based on public sources. A 5-state Markov
model was developed to simulate the disease progression:
disease-free survival, recurrence, metastatic, cardiac events and
death. Only direct costs were considered in the calculation and a
lifetime perspective was assumed. A discounting rate of 5% was
adopted according to DECIT local guidelines for economic
evaluation. Probabilistic sensitivity analysis was performed to
account the robustness of the estimates. RESULTS: Trastuzumab
treatment costs were higher than those of the observational arm:
a R$ 43,363 increment for trastuzumab. The use of trastuzumab
reduced time in the metastatic state by 1.15 years and then
cost-offsets of R$67,472 were observed as a consequence. For the
total period, trastuzumab arm presented an increase in dis-
counted overall survival of 1.36 life years and a discounted
quality-adjusted survival of 1.44 QALYs, and also a favorable
ICER of R$30,040 per QALY. CONCLUSIONS: This cost-
effectiveness analysis suggests that the use of trastuzumab in
adjuvant therapy for patients with early breast cancer HER-2
positive brings important clinical beneﬁts to the patients and in
addition is a cost-effective alternative within the Brazilian public
health care system perspective.
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OBJECTIVES: The purpose of this analysis was to examine the
economic efﬁciency of treating metastatic colorectal cancer
(mCRC) with XELOX +/- Bevacizumab every three weeks versus
FOLFOX-4 +/– Bevacizumab every two weeks as ﬁrst-line treat-
ment. METHODS: The decision model was developed from the
social perspective. The mean annual total cost per patient treated
was estimated considering the annual drug costs, the annual cost
associated with the drug administration and the annual cost to
treat the adverse effects induced by each regime. We include the
social costs derived from the time that the patient incurred in the
chemotherapy administration process and the time consumed by
travelling to the health care centre. According to the trial, the
treatments with XELOX and FOLFOX-4 have a similar effec-
tiveness proﬁles. RESULTS: Total direct annual cost from the
perspective of the health care payer was €639 inferior with
XELOX when compared with FOLFOX-4 and €1887 inferior
when it was compared [XELOX + Bevacizumab] with
[FOLFOX-4 + Bevacizumab]. Including indirect costs, the
regimes with XELOX presented a lower cost of €1534 (without
bevacizumab) and €3.003 (with bevacizumab) when they are
compared with the respective regimes with FOLFOX-4. CON-
CLUSIONS: The smaller annual cost of the chemotherapy based
on XELOX it is due to a relatively smaller costs associated to the
administration of oral capecitabine; the implantation of a central
venous access device which is not needed in the great majority of
patients following the XELOX regimes; and for the smaller
number of administration cycles throughout the 48 weeks period
under study.
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